WO2021063967A1
|
|
Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
|
US2021093698A1
|
|
Treatment of type 2 diabetes mellitus
|
WO2021048035A1
|
|
A monitoring system and method
|
WO2021044004A1
|
|
Oligonucleotides containing nucleotide analogs
|
WO2021037972A1
|
|
Compositions and methods for inhibiting pcsk9
|
WO2021037844A1
|
|
Sensor assembly
|
WO2021037818A1
|
|
Medicament container with electronic identifier
|
WO2021032653A1
|
|
Closure for medicament container
|
WO2021030270A1
|
|
Predicting patient responses to a chemical substance
|
WO2021009022A1
|
|
Fluid dispensing device
|
WO2021001254A1
|
|
Awakening electronics in an injection device
|
WO2021001256A1
|
|
Chemical wake-up mechanism for active electronics in pen injectors
|
WO2021001259A1
|
|
Wakening electronics in an injection device
|
WO2020260221A1
|
|
Injection device with a filling level indicator
|
WO2020260220A1
|
|
Injection device
|
WO2020249776A1
|
|
Apparatus for detecting a dose of medicament delivered from an injection device
|
WO2020249777A1
|
|
Electronically-controlled capturing system for drug delivery systems
|
WO2020249775A1
|
|
Drug delivery device
|
US2020399391A1
|
|
Anti-cd38 antibodies and formulations
|
WO2020245234A1
|
|
Medicament container
|